Literature DB >> 17401539

Plasma amino acids and neopterin in healthy persons with Down's syndrome.

A W Coppus1, D Fekkes, W M A Verhoeven, S Tuinier, J I M Egger, C M van Duijn.   

Abstract

In persons with Down's syndrome (DS) immunological abnormalities as well as hypothyroidism and Alzheimer type dementia are frequently observed. In addition, the activity of the enzyme cystathionine beta-synthase (CBS) is over-expressed which results in an altered homocysteine metabolism. In the present study, 48 older healthy DS persons without signs of dementia, psychiatric or somatic comorbidity and free of medication were analyzed for plasma levels of amino acids, neopterin and monoaminergic metabolites. Data were compared with those obtained from age and sex matched healthy controls. It was found that the spectrum of amino acids showed widespread differences in that levels of nearly all essential amino acids were lower in DS patients as compared to healthy controls. In addition, a significantly lower methionine and higher taurine concentration were observed which is in accordance with a disturbed homocysteine metabolism. With respect to the monoamine metabolites, the concentration of 5-hydroxyindoleacetic acid was not altered whereas that of homovanillic acid was significantly increased. Finally, the concentration of the immune activation marker neopterin was increased in persons with DS. It is concluded that healthy DS persons of older age show extensive biochemical abnormalities suggesting a compromised homocysteine metabolism, an activated cell-mediated immune response and an enhanced turnover of dopamine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401539      PMCID: PMC2794348          DOI: 10.1007/s00702-007-0656-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


Introduction

Down’s syndrome (DS) or trisomy 21 is the most common form of intellectual disability with an overall prevalence of 1.42/1000 that increases significantly with maternal age (Bray et al., 1998). Immunological abnormalities like functional impairments in fagocytes with low chemotactic ability as well as the depressed production of cytokines are intrinsic to the chromosomal disorder and result in an increased morbidity and mortality from infectious diseases (Ugazio et al., 1990). In addition, DS is associated with hypothyroidism in 20–40% of the patients and with neuropsychiatric disorders of which depression and Alzheimer-type dementia are the most frequent (Lovell and Reiss, 1993; Prasher, 1999; Bush and Beail, 2004). Since the activity of the enzyme cystathionine β-synthase (CBS), which is encoded on chromosome 21 (21q22.3), is associated with the level of intelligence and with neuropsychiatric disorders (Abbott et al., 1987; Barbaux et al., 2000), the concentration of CBS was recently investigated in postmortem brains of DS persons (Ichinohe et al., 2005). It was found that the concentration of CBS was three times higher as compared to brain levels of normal individuals. CBS catalyzes the conversion of homocysteine and serine into cystathionine. The latter dipeptide is further metabolized into the amino acids cysteine and eventually to taurine. In humans, the sole source of homocysteine is through dietary intake of the essential amino acid methionine (Selhub et al., 1999; Ward et al., 2000). Thus, the over-expression of CBS in persons with DS may alter homocysteine metabolism resulting in a metabolic imbalance such that folate-dependent resynthesis of methionine is compromised, and may be in favour of the transsulfuration pathway, leading eventually to increased levels of taurine (Huxtable, 1992). Due to the dosage effect of CBS, a decrease in plasma concentration of serine was found in DS persons. In addition, an increase in plasma lysine, which was explained by generalized premature aging in DS, was observed (Mircher et al., 1997). Another amino acid abnormality is a decrease of systemic glutamate uptake as assessed by measuring glutamate uptake in platelets and fibroblasts from DS persons (Begni et al., 2003). The authors suggest the use of this peripheral model as a biochemical ex vivo marker of a central glutamatergic dysfunction. Excessive glutamatergic stimulation as a consequence of glutamate uptake deficits could be responsible for neuronal suffering, excitoxicity and cell death, and may play a key role in the pathophysiology of neuropsychiatric disorders (review: Van der Heijden et al., 2004). Apart from the abovementioned amino acid abnormalities, impaired immunological function in DS persons results in increased serum neopterin levels (Mehta et al., 2005). Neopterin is not only an immune activator for the cell-mediated immune response, but also induces or enhances cytotoxicity and exhibits antioxidant properties (Hamerlinck, 1999). This observation is consistent with the increased susceptibility of DS persons to bacterial and viral infections (Cossarizza et al., 1990). No studies have been reported on the measurement of peripheral precursors or metabolites of the neurotransmitters serotonin and dopamine in DS. Since serotonin is involved in brain growth and maturation, and experimentally induced high dopamine turnover may give rise to toxic metabolites and neurodegeneration (Ogawa et al., 1993; Alexander et al., 1997; Kupsch et al., 2001), measurement of peripheral correlates of central serotonin and dopamine metabolism is also warranted. Since at least 40% of circulating homovanillic acid (HVA) originates form the brain, the plasma HVA concentration is thought to be a fairly good indicator of the changes in dopamine metabolism in the brain (Kendler et al., 1982). In addition, plasma 5-hydroxyindoleacetic acid (5-HIAA) is suggested to be an indicator of brain serotonergic activity (Meltzer, 1989). The present study was designed to investigate peripheral parameters that reflect changes in homocysteine metabolism, immune function and monoaminergic neurotransmission in a group older non-demented healthy persons with DS. To this end, especially the sulphur containing amino acids methionine and taurine as well as serine, glycine, glutamate, lysine, tryptophan and the other large neutral amino acids (LNAA) were measured. The ratio of tryptophan to LNAA is a fairly good indicator of central serotonin synthesis. Concentrations of the dopamine and serotonin metabolites HVA and 5-HIAA were determined as well as the levels of the immune activation marker neopterin.

Materials and methods

Subjects

Over a period of 4 years a community based sample of 505 DS persons aged 45 year and older from the Southern and the South-Western parts of the Netherlands was collected. The study protocol was approved by the Medical Ethetical Committee of the Erasmus University Medical Centre in Rotterdam, The Netherlands (protocol number: MEC 185.974/1999/202). In addition, the ethical committee of the local institutions provided approval. Written informed consent was obtained from the legal representatives. Details of the study population and the used screening instruments are presented elsewhere (Coppus et al., 2006). For the present study persons were excluded in case of any relevant somatic comorbidity, including hypothyroidism and epilepsy, or the presence of a depressive disorder and signs of dementia. All persons were free of medication, including the use of folic acid, and did not smoke. The study group comprised 48 persons with DS (female: 11; male: 37; mean age: 50 ± 4.8 years) of whom 2 had to be excluded because of laboratory problems, and was compared to a group of 48 age and sex matched healthy controls (female: 16; male: 32; mean age: 50.2 ± 9.1 years).

Biochemical analyses

Plasma amino acids are analyzed by high-performance liquid chromatography (HPLC) using pre-column derivatization with o-phthaldialdehyde (Fekkes et al., 1995). The tryptophan-ratio (Trp-ratio) is calculated by dividing the total tryptophan level by the sum of the other large neutral amino acids (LNAA), i.e. valine, isoleucine, leucine, tyrosine and phenylalanine, which compete for the transport of tryptophan through the blood- brain barrier. The tyrosine-ratio (Tyr-ratio) is calculated in the same manner by substituting tryptophan for tyrosine. The concentrations of the monoamine metabolites 5-HIAA and HVA are analyzed by HPLC and electrochemical detection (Fekkes et al., 1997). The concentration of neopterin in plasma is determined as previously described (Hoekstra et al., 2001).

Statistical analyses

For statistical comparisons between persons with DS and controls, the unpaired t-test was used because all data sets showed a normal distribution. Normality of the distribution was tested with the Kolmogorov-Smirnov test. A value of p<0.05 was considered to be statistically significant. In case of finding statistically significant values for biochemical parameters, discriminant analysis was performed in order to assess the potential for further differentiating DS persons from controls, and to establish their relative contribution to the group difference.

Results

As can be inferred from Table 1, the concentrations of methionine, glutamate and all LNAA are significantly decreased in the DS group as compared to the control group. Of the LNAA, tryptophan shows the lowest significance. The concentrations of taurine and glycine are significantly increased in DS persons as compared to controls, whereas the level of glutamate is significantly decreased. In addition, the Trp-ratio but not the Tyr-ratio, is significantly higher in the DS group compared to the controls.
Table 1

Plasma levels (mean ± SD) of biochemical parameters in DS persons and controls

Biochemical parameterDS patients (n)Healthy controls (n)Significance
Tryptophan (µmol/1)47.1 ± 6.1 (46)50.4 ± 9.0 (48)p = 0.040
Tyrosine (µmol/1)61.9 ± 12.6 (46)71.0 ± 17.3 (48)p = 0.004
Valine (µmol/1)226.5 ± 42.8 (46)286.2 ± 59.7 (48)p<0.000
Phenylalanine (µmol/1)58.0 ± 8.5 (46)63.1 ± 10.0(48)p = 0.010
Isoleucine (µmol/1)61.2 ± 11.7 (46)82.7 ± 24.1 (48)p<0.000
Leucine (µmol/1)122.6 ± 20.9 (46)148.5 ± 31.8 (48)p<0.000
Methionine (µmol/1)25.6 ± 4.7 (46)32.0 ± 6.5 (48)p<0.000
Taurine (µmol/1)53.9 ± 11.8 (46)42.9 ± 7.6 (48)p<0.000
Serine (µmol/1)103.7 ± 17.3 (46)109.8 ± 19.1 (48)p = 0.106
Lysine (µmol/1)199.3 ± 31.8 (46)186.3 ± 35.7 (48)p = 0.065
Glycine (µmol/1)244.6 ± 48.7 (46)213.0 ± 43.5 (48)p = 0.001
Glutamate (µmol/1)37.4 ± 22.5 (46)47.7 ± 20.3 (48)p = 0.021
Trp-ratio9.0 ± 1.5 (46)7.9 ± 1.5 (48)p <0.000
Tyr-ratio12.2 ± 3.3 (46)11.3 ± 2.1 (48)p = 0.113
Neopterin (nmol/1)20.4 ± 5.8 (43)17.4 ± 3.7 (28)p = 0.008
HVA (nmol/l)a64.1 ± 16.5 (45)53.2 ± 12.9 (41)p = 0.001
5-HIAA (nmol/l)b43.5 ± 9.0 (45)41.5 ± 12.9 (42)p = 0.405

a HVA Homovanillic acid.

b 5-HIAA 5-Hydroxyindoleacetic acid.

Plasma levels (mean ± SD) of biochemical parameters in DS persons and controls a HVA Homovanillic acid. b 5-HIAA 5-Hydroxyindoleacetic acid. With respect to neopterin, values in the DS group are significantly increased as compared to the control group. Furthermore, plasma HVA concentrations are significantly higher in the DS group, whereas no differences are found regarding 5-HIAA concentrations. Finally, discriminant analysis (stepwise method) of the biochemical parameters with p-values <0.001 (valine, isoleucine, leucine, methionine, taurine and Trp-ratio) results in a discriminant function with valine, methionine and taurine as major predictors. Classification results are good: 84.8% of the DS persons were correctly classified as were 83.3% of the controls. As a whole 16% was wrongly classified.

Discussion

In the present study biochemical parameters related to neurotransmission and immunological function were investigated in a group of older persons with Down’s syndrome. It was found that the spectrum of amino acids shows widespread differences in the DS group as compared to controls. More specific, the amino acids valine, methionine and taurine were demonstrated to differentiate persons with DS from controls. Nearly all values of amino acids are lower in the DS group, which cannot be explained from dietary effects since all persons were provided with well balanced meals. Besides, Ciaccio et al. (2003) reported that dietary measures over one year have an only marginal influence on the plasma concentration of amino acids in children with DS. With respect to the CBS-related parameters, plasma methionine was found to be significantly lower, while taurine was higher. In addition, plasma serine was slightly decreased in DS persons. These observations are in accordance with an over-expression of the CBS-gene in DS (Chadefaux et al., 1985; Progribna et al., 2001; review: Chango et al., 2002) and are also in line with results concerning serine and taurine plasma concentrations as reported by Mircher et al. (1997). Although homocysteine was unfortunately not measured in this primarily epidemiological study, these data corroborate an altered homocysteine metabolism in persons with DS and are as such in line with the lowered plasma concentration of homocysteine reported by Pogribna et al. (2001). Other investigators, however, reported increased concentrations of homocysteine (Brattstrom et al., 1989; Guéant et al., 2005). As reviewed by Townsend et al. (2004), the sulphur containing amino acids methionine, homocysteine and taurine are involved in the maintenance and integrity of cellular systems by influencing cellular redox state and cellular capacity to detoxify toxic compounds, free radicals and reactive oxygen species. An imbalance of these amino acids in DS persons may indicate neuropathological changes in this group. The increased Trp-ratio in the DS group suggests an enhanced availability of tryptophan for the synthesis of serotonin in the central nervous system. Whether central serotonergic neurotransmission is increased in DS persons cannot be concluded from this study, especially since the plasma concentration of 5-HIAA is not changed. The latter parameter, however, is only a very weak and indirect measure of central serotonergic activity (Lambert et al., 1995). On the other hand, plasma HVA concentrations are signifi- cantly increased, which is an indication of a higher turnover of dopamine that was reported previously also in cerebrospinal fluid studies in persons with DS (Kay et al., 1987; Schapiro et al., 1987). Neopterin is increased in the DS group as compared to controls. This finding is in agreement with the observations by Metha et al. (2005) who additionally reported that increase of neopterin is not correlated with age and sex. High concentrations of neopterin as seen in DS is consistent with the impaired immune function that was reported in persons with DS (Nespoli et al., 1993; Park et al., 2000). In conclusion, in the present study of persons with DS without any signs of dementia, somatic and/or neuropsychiatric comorbidity and free of any medication, extensive biochemical abnormalities are found suggesting a compromised homocysteine metabolism, an activated cellmediated immune response and an enhanced turnover of dopamine. Interestingly, a few peripheral biochemical parameters appeared to have a marked potential to differentiate between DS persons from controls.
  38 in total

1.  Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

Authors:  A Kupsch; J Sautter; M E Götz; W Breithaupt; J Schwarz; M B Youdim; P Riederer; M Gerlach; W H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

2.  Cerebrospinal fluid monoamines in Down's syndrome adults at different ages.

Authors:  M B Schapiro; A D Kay; C May; A K Ryker; J V Haxby; S Kaufman; S Milstien; S I Rapoport
Journal:  J Ment Defic Res       Date:  1987-09

3.  Fluctuations in dietary methionine intake do not alter plasma homocysteine concentration in healthy men.

Authors:  M Ward; H McNulty; K Pentieva; J McPartlin; J J Strain; D G Weir; J M Scott
Journal:  J Nutr       Date:  2000-11       Impact factor: 4.798

4.  Homocysteine metabolism in children with Down syndrome: in vitro modulation.

Authors:  M Pogribna; S Melnyk; I Pogribny; A Chango; P Yi; S J James
Journal:  Am J Hum Genet       Date:  2001-06-05       Impact factor: 11.025

5.  Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase.

Authors:  L Brattström; B Israelsson; L Tengborn; B Hultberg
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

6.  Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness.

Authors:  M H Abbott; S E Folstein; H Abbey; R E Pyeritz
Journal:  Am J Med Genet       Date:  1987-04

Review 7.  [One carbon metabolism and trisomy 21: analysis of the genetic polymorphism].

Authors:  A Chango; C Mircher; S J James; M O Réthoré; J-P Nicolas
Journal:  Ann Biol Clin (Paris)       Date:  2002 Nov-Dec       Impact factor: 0.459

8.  Altered glutamate uptake in peripheral tissues from Down syndrome patients.

Authors:  Barbara Begni; Laura Brighina; Lorenzo Fumagalli; Simona Andreoni; Enrico Castelli; Claudia Francesconi; Roberto Del Bo; Nereo Bresolin; Carlo Ferrarese
Journal:  Neurosci Lett       Date:  2003-06-05       Impact factor: 3.046

Review 9.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Cerebrospinal fluid monoaminergic metabolites are elevated in adults with Down's syndrome.

Authors:  A D Kay; M B Schapiro; A K Riker; J V Haxby; S I Rapoport; N R Cutler
Journal:  Ann Neurol       Date:  1987-04       Impact factor: 10.422

View more
  17 in total

1.  Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain.

Authors:  J London; F K Ndiaye; L C Bui; B Souchet; F Daubigney; C Magnan; S Luquet; J Dairou; N Janel; C Rouch
Journal:  Mol Neurobiol       Date:  2018-09-20       Impact factor: 5.590

Review 2.  Antioxidants in Down syndrome.

Authors:  Ira T Lott
Journal:  Biochim Biophys Acta       Date:  2011-12-21

3.  Red blood cell metabolism in Down syndrome: hints on metabolic derangements in aging.

Authors:  Rachel Culp-Hill; Connie Zheng; Julie A Reisz; Keith Smith; Angela Rachubinski; Travis Nemkov; Eric Butcher; Ross Granrath; Kirk C Hansen; Joaquín M Espinosa; Angelo D'Alessandro
Journal:  Blood Adv       Date:  2017-12-21

4.  Urinary biomarkers and obstructive sleep apnea in patients with Down syndrome.

Authors:  Ibrahim Elsharkawi; David Gozal; Eric A Macklin; Lauren Voelz; Gil Weintraub; Brian G Skotko
Journal:  Sleep Med       Date:  2017-03-07       Impact factor: 3.492

5.  DHFR 19-bp deletion and SHMT C1420T polymorphisms and metabolite concentrations of the folate pathway in individuals with Down syndrome.

Authors:  Cristiani Cortez Mendes; Aline Maria Zanchetta de Aquino Raimundo; Luciana Dutra Oliveira; Bruna Lancia Zampieri; Gustavo Henrique Marucci; Joice Matos Biselli; Eny Maria Goloni-Bertollo; Marcos Nogueira Eberlin; Renato Haddad; Maria Francesca Riccio; Hélio Vannucchi; Valdemir Melechco Carvalho; Érika Cristina Pavarino
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-19

6.  Genetic polymorphisms modulate the folate metabolism of Brazilian individuals with Down syndrome.

Authors:  J M Biselli; B L Zampieri; E M Goloni-Bertollo; R Haddad; M F R Fonseca; M N Eberlin; H Vannucchi; V M Carvalho; E C Pavarino
Journal:  Mol Biol Rep       Date:  2012-08-19       Impact factor: 2.316

Review 7.  Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.

Authors:  Panagiotis Zis; Andre Strydom
Journal:  Free Radic Biol Med       Date:  2017-09-01       Impact factor: 7.376

8.  Brain phenotype of transgenic mice overexpressing cystathionine β-synthase.

Authors:  Vinciane Régnier; Jean-Marie Billard; Sapna Gupta; Brigitte Potier; Stéphanie Woerner; Evelyne Paly; Aurélie Ledru; Sabrina David; Sabrina Luilier; Jean-Charles Bizot; Guido Vacano; Jan P Kraus; David Patterson; Warren D Kruger; Jean M Delabar; Jaqueline London
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

9.  Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress.

Authors:  Panagiotis Zis; Patrick McHugh; Andrew McQuillin; Domenico Praticò; Mark Dickinson; Sima Shende; Zuzana Walker; Andre Strydom
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

10.  Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models.

Authors:  Alain D Dekker; Yannick Vermeiren; Christelle Albac; Eva Lana-Elola; Sheona Watson-Scales; Dorota Gibbins; Tony Aerts; Debby Van Dam; Elizabeth M C Fisher; Victor L J Tybulewicz; Marie-Claude Potier; Peter P De Deyn
Journal:  Neurobiol Dis       Date:  2017-06-15       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.